NuCana BioMed is an oncology focused biopharmaceutical company dedicated to the development and commercialisation of new medicines to treat patients with cancer.
The ProTide Technology Platform has the potential to transform chemotherapy to targeted therapy. Our ProTides have been designed to target specific patient populations for whom existing chemotherapy is not likely to be effective. By overcoming the key resistance pathways, ProTides aim to significantly improve the efficacy, broaden the clinical utility, and improve the safety profile of many established anticancer agents.
Our management team has extensive experience of building successful biopharmaceutical companies. This includes the formation and subsequent growth of Bioenvision into a NASDAQ National listed, global biopharmaceutical company. Bioenvision was acquired by Genzyme Corporation for US$345 million in October 2007.